NEW YORK, July 31, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC announces that a securities class action has been filed in the United States District Court for the Middle District of Florida on behalf of those who purchased shares of Accentia Biopharmaceuticals, Inc. ("Accentia") (OTC: ABPI) or Biovest International, Inc. ("Biovest") (OTCQB:BVTIQ), a majority-owned subsidiary of Accentia during the period between July 26, 2008 through August 14, 2012 inclusive (the "Class Period").
The Complaint charges Accentia and certain officers and directors of Accentia and Biovest with violations of federal securities laws. The Complaint alleges that the FDA informed Biovest that the results of a Phase III clinical trial for BiovaxID, a potential vaccine for the treatment of non-Hodgkin's lymphoma, did not support an application for approval of BiovaxID. Contrary to the FDA advice, Defendants made numerous statements in press releases and securities filings that gave the misleading impression that BiovaxID vaccine was on the path to FDA approval.
Plaintiff seeks to recover damages on behalf of shareholders who purchased common stock of the companies during the Class Period described above.
No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. September 30, 2013 is the deadline for investors to seek a lead plaintiff appointment. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC